Mustafa Khasraw
Overview:
I am a medical oncologist, neuro-oncologist, tenured professor of medicine and neurooncology, and Deputy Director of the Center for Cancer Immunotherapy, Duke Cancer Institute, where are tasked to speed up clinical research and translation for scientists across all departments and all tumor types at Duke, who have made discoveries that show promise for developing new immunotherapies.
I am leading several clinical and translational programs with significant laboratory collaborations with an interest in innovative trials designed to improve the outcome of patients with cancers of the CNS. In addition, I am the principal investigator on first in human phase I immunotherapy clinical trials in solid tumors.
I serve as an advisor and grant reviewer for several non-profits and patient advocacy groups. I am a Fellow of the Royal Australasian College of Physicians and an Elected Fellow of the Royal College of Physicians (UK).
Positions:
Professor of Neurosurgery
Professor in Medicine
Member of the Duke Cancer Institute
Education:
M.D. 2001
Grants:
Astellas 1951-CL-0101
Celldex CDX-527
Publications:
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.
Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.
Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy.
Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage.
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.
Research Areas:
